Advertisement

46-Year-Old with Psoriasis and Chronic Hepatitis C

  • Kevin K. Wu
  • Michael P. Lee
  • Jashin J. Wu
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

Hepatitis C (HCV) is a viral infection that is associated with a higher risk of psoriasis. Treatment of psoriasis in patients with comorbid HCV is challenging because many psoriasis therapies are hepatotoxic or immunosuppressive. First-line treatments for psoriasis patients with concomitant HCV include phototherapy, topical therapies, and apremilast. Methotrexate should be avoided due to potential hepatotoxicity.

Keywords

Hepatitis C Psoriasis Hepatotoxic Phototherapy TNF inhibitors Apremilast Methotrexate 

References

  1. 1.
    CDC. Viral hepatitis statistics and surveillance. 2016. Retrieved from United States.Google Scholar
  2. 2.
    Imafuku S, Naito R, Nakayama J. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol. 2013;40(10):813–8.  https://doi.org/10.1111/1346-8138.12240.CrossRefPubMedGoogle Scholar
  3. 3.
    Gabr SA, Berika MY, Alghadir AH. Apoptosis and clinical severity in patients with psoriasis and HCV infection. Indian J Dermatol. 2014;59(3):230–6.  https://doi.org/10.4103/0019-5154.131377.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chun K, Afshar M, Audish D, Kabigting F, Paik A, Gallo R, Hata T. Hepatitis C may enhance key amplifiers of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(4):672–8.  https://doi.org/10.1111/jdv.13578.CrossRefPubMedGoogle Scholar
  5. 5.
    Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;61(6):1044–55.  https://doi.org/10.1016/j.jaad.2009.03.044.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim GW, Jwa SW, Song M, Kim HS, Kim BS, Kim MB, Ko HC. Extensive psoriasis induced by pegylated interferon alfa-2a and ribavirin in the treatment of chronic hepatitis C. Ann Dermatol. 2013;25(4):479–82.  https://doi.org/10.5021/ad.2013.25.4.479.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J. 2000;76(896):365–7.CrossRefGoogle Scholar
  8. 8.
    Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444–55.  https://doi.org/10.3748/wjg.v22.i28.6444.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481–2.  https://doi.org/10.1111/jdv.14301.CrossRefPubMedGoogle Scholar
  10. 10.
    Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90.  https://doi.org/10.1016/j.bcp.2012.01.001.CrossRefPubMedGoogle Scholar
  11. 11.
    Kaushik SB, Lebwohl MG. CME Part II psoriasis: which therapy for which patient focus on special populations and chronic infections. J Am Acad Dermatol. 2018;80:43–53.  https://doi.org/10.1016/j.jaad.2018.06.056.CrossRefPubMedGoogle Scholar
  12. 12.
    Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50(9):1700–11.  https://doi.org/10.1093/rheumatology/ker190.CrossRefGoogle Scholar
  13. 13.
    Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315–22.CrossRefGoogle Scholar
  14. 14.
    Heck JA, Meng X, Frick DN. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem Pharmacol. 2009;77(7):1173–80.  https://doi.org/10.1016/j.bcp.2008.12.019.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–16.  https://doi.org/10.1111/bjd.12045.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295–303.  https://doi.org/10.1111/bjd.12461.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kevin K. Wu
    • 1
  • Michael P. Lee
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  2. 2.Eastern Virginia Medical SchoolNorfolkUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations